Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer
2013 (English)In: Menopause: The Journal of the North American Menopause, ISSN 1072-3714, E-ISSN 1530-0374, Vol. 20, no 2, 162-168 p.Article in journal (Refereed) Published
The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.
A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.
In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitor-treated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.
Our findings suggest that sexual dysfunction in aromatase inhibitor-treated women is a greatly underestimated problem.
Place, publisher, year, edition, pages
2013. Vol. 20, no 2, 162-168 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-185540DOI: 10.1097/gme.0b013e31826560daISI: 000314342600010PubMedID: 22990756OAI: oai:DiVA.org:uu-185540DiVA: diva2:572043